Trinity Biotech Plc Long Term Debt

Trinity Biotech Plc (TRIB) currently reports a long-term debt of $27M as of December 2025. That compares with $98M in the prior-year period — down 72.4% year over year. Use the charts on this page to explore Trinity Biotech Plc's long-term debt history and peer comparisons.

Trinity Biotech Plc's long-term debt decreased from $98M to $27M — a 72.4% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Trinity Biotech Plc reported $27M in long-term debt as of December 2025. That compares with $98M in the prior-year period — down 72.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $27M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Trinity Biotech Plc, and consider following TRIB for alerts when major investors trade the stock.

Trinity Biotech Plc is classified in the Healthcare sector. On long-term debt, it currently shows $27M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TRIB with unrelated industries.